Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Alžběta Zavřelová und 9 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, H…. Hauptthemen laut MEDLINE: Linezolid, Sepsis, Anti-Bacterial Agents, Models, Biological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Health.
Themen: Sepsis
Abstract (Originalsprache)
The objective of this study was to develop a population pharmacokinetic model for linezolid in hematooncological patients with sepsis, and to propose dosing optimization based on pharmacokinetic covariates that would lead to improved achievement of the PK/PD target. Therapeutic drug monitoring data from hematooncological patients treated with linezolid for suspected or proven sepsis were analyzed. A pharmacokinetic population model for linezolid was constructed using a nonlinear mixed‐effects modeling approach. Monte Carlo simulations were then used to compare various dosing regimens in terms of PK/PD target attainment. A total of 197 linezolid serum concentrations obtained from 22 patients were included in the analysis. Patients' age was found to be the most predictive covariate for linezolid pharmacokinetics. In a patient with a median age of 59 years, the volume of distribution and clearance of linezolid were 46.2 L and 12.1 L/h, respectively. During the first 4 days of therapy, linezolid clearance decreased by 33%. The probability of PK/PD target attainment increased through the individualization of the dose according to the patient's age, administration of a loading dose, and administration of linezolid via continuous infusion. For this scenario, an easy‐to‐use nomogram was designed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 4th Department of Internal Medicine - Hematology, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
- Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic.
- Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
ORCID-Profile: Martin Šíma
Förderung
- Ministry of Health
Zitieren
APA
Zavřelová, A., Merdita, S., Žák, P., Radocha, J., Víšek, B., Lánská, M., Maláková, J., Michálek, P., Slanař, O., & Šíma, M. (2025). Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis. Clinical and Translational Science. https://doi.org/10.1111/cts.70346
Vancouver
Zavřelová A, Merdita S, Žák P, Radocha J, Víšek B, Lánská M, et al. Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis. Clinical and Translational Science. 2025. doi:10.1111/cts.70346
BibTeX
@article{Zavelov2025,
author = {Zavřelová, Alžběta and Merdita, Sara and Žák, Pavel and Radocha, Jakub and Víšek, Benjamin and Lánská, Miriam and Maláková, Jana and Michálek, Pavel and Slanař, Ondřej and Šíma, Martin},
title = {Population Pharmacokinetic Model‐Based Optimization of Linezolid Dosing in Hematooncological Patients With Suspected or Proven Gram‐Positive Sepsis},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70346}
}
EUVIMED